ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares fell in after-hours trading on Wednesday after the company provided commercial and financial updates, including no new formulary additions for Neffy in the July 2026 coverage cycle.
SPRY closed Wednesday’s regular session at $10.54, up 2.53%. In after-hours trading, shares fell to $8.00, down 24.08%.
ARS Pharmaceuticals is a biopharmaceutical company focused on developing needle-free treatments. Its lead product, Neffy, is an epinephrine nasal spray used for emergency treatment of severe allergic reactions, including anaphylaxis.
No New Coverage Decisions For Neffy
ARS Pharmaceuticals said no new commercial formulary additions or coverage decisions were issued for Neffy in the July 1, 2026, cycle.
